Biocon Launches Yesafili Biosimilar to Eylea in U.S.
BENGALURU, India, and BRIDGEWATER, N.J., Aug. 3, 2026 Biocon Limited has announced the U.S. commercial launch of Yesafili™ (aflibercept-jbvf),...
BLA
Advertisement
Can-Fite Launches Phase 2 Piclidenoson Trial for Lowe Syndrome
RAMAT GAN, Israel, Aug. 3, 2026 Can-Fite BioPharma Ltd. has launched its first clinical development program evaluating Piclidenoson for...
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
Fresenius Kabi’s Vedolizumab Biosimilar Accepted for FDA and EMA Review
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
Polpharma Biologics Secures FDA and EMA Review for PB016
ROTKREUZ, Switzerland, July 31, 2026 Polpharma Biologics International AG announced that the U.S. Food and Drug Administration (FDA) and...
Advertisements
Ascletis Reports ASC37 Shows Superior Weight Loss in Obesity Study
Hong Kong, July 27, 2026 Ascletis Pharma Inc. announced that its investigational ASC37, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist,...
Dyne Therapeutics Advances DMD Program with FDA Acceptance
WALTHAM, Mass., July 20, 2026 Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that the U.S. Food and Drug Administration (FDA)...
Avance Clinical Unveils Asia Growth Strategy at BIO Asia–Taiwan
TAIPEI, Taiwan | July 10, 2026 Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO), has announced its participation...
Leads Biolabs Secures Priority Review for Opamtistomig
NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...
Invivyd Receives FDA EUA Termination Notice for PEMGARDA
NEW HAVEN, Conn., July 6, 2026 Invivyd announced that the U.S. Food and Drug Administration (FDA) has issued a...
Advertisement
